Vapotherm Inc Forecasted to Earn FY2019 Earnings of ($2.66) Per Share (NYSE:VAPO)

Vapotherm Inc (NYSE:VAPO) – Research analysts at William Blair upped their FY2019 earnings estimates for shares of Vapotherm in a report issued on Wednesday, November 6th. William Blair analyst M. Kaczor now anticipates that the company will post earnings per share of ($2.66) for the year, up from their prior forecast of ($3.08). William Blair also issued estimates for Vapotherm’s Q4 2019 earnings at ($0.71) EPS, Q1 2020 earnings at ($0.83) EPS, Q2 2020 earnings at ($0.68) EPS, Q3 2020 earnings at ($0.70) EPS, Q4 2020 earnings at ($0.69) EPS and FY2020 earnings at ($2.63) EPS.

Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Vapotherm from a “buy” rating to a “hold” rating in a research report on Saturday, October 5th. ValuEngine upgraded Vapotherm from a “buy” rating to a “strong-buy” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Vapotherm currently has an average rating of “Buy” and an average price target of $23.67.

Shares of Vapotherm stock opened at $9.48 on Monday. The company has a current ratio of 7.61, a quick ratio of 6.81 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $182.59 million and a PE ratio of -0.69. The business’s 50-day moving average price is $9.92 and its 200-day moving average price is $14.90. Vapotherm has a 12 month low of $7.60 and a 12 month high of $24.63.

Vapotherm (NYSE:VAPO) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.11. The firm had revenue of $10.81 million for the quarter, compared to analyst estimates of $11.10 million. Vapotherm had a negative return on equity of 107.95% and a negative net margin of 110.06%.

In other Vapotherm news, CEO Joseph Army acquired 10,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $100,000.00. Also, insider John Landry acquired 3,000 shares of the company’s stock in a transaction on Thursday, September 5th. The stock was acquired at an average price of $10.34 per share, with a total value of $31,020.00. Following the acquisition, the insider now owns 97,703 shares in the company, valued at approximately $1,010,249.02. The disclosure for this purchase can be found here. Insiders have purchased a total of 76,382 shares of company stock valued at $731,807 over the last 90 days. 34.40% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new stake in Vapotherm in the 3rd quarter worth approximately $42,000. Taylor Frigon Capital Management LLC lifted its holdings in Vapotherm by 234.2% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 125,527 shares of the company’s stock worth $1,189,000 after buying an additional 87,964 shares during the period. Arnhold LLC lifted its holdings in Vapotherm by 25.0% in the 3rd quarter. Arnhold LLC now owns 50,000 shares of the company’s stock worth $474,000 after buying an additional 10,012 shares during the period. Rhumbline Advisers purchased a new stake in Vapotherm in the 3rd quarter worth approximately $113,000. Finally, Perceptive Advisors LLC lifted its holdings in Vapotherm by 12.7% in the 2nd quarter. Perceptive Advisors LLC now owns 1,404,470 shares of the company’s stock worth $32,302,000 after buying an additional 158,155 shares during the period. Institutional investors and hedge funds own 51.51% of the company’s stock.

Vapotherm Company Profile

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Recommended Story: How does equity income fit into an investing strategy?

Earnings History and Estimates for Vapotherm (NYSE:VAPO)

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.